Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Shionogi Files Japan, US NDAs for Naldemedine for Opioid-Induced Constipation
March 31, 2016
- Shionogi Says Complaint against ViiV-Related Tax Reassessment Rejected, Poised to Go to Court
March 30, 2016
- Astellas, Mitsubishi Tanabe to Share Compound Libraries
March 30, 2016
- In a Setback, FDA Rebuffs Label Expansion for Takeda’s Brintellix
March 30, 2016
- PeptiDream, Asahi Kasei Pharma Forge Research Collaboration
March 29, 2016
- Mylan Japan Offers Severance Package for 110 Sales Reps
March 29, 2016
- ASKA Shoots for Group Annual Sales of 70 Billion Yen in Five Years
March 29, 2016
- Asian PII Study Launched for Solasia’s PTCL Treatment: Meiji Seika Pharma
March 29, 2016
- Torii Looks to Ramp Up Sales in Allergen Sector, Expand Indications for Sublingual Therapies
March 28, 2016
- IP High Court Rules in Favor of Chugai in Oxarol Patent Suit
March 28, 2016
- Lilly Joins Hands with NCC on Biomarkers for Advanced Gastric Cancer
March 28, 2016
- Global PIII for Xtandi Launched for Hormone Sensitive Prostate Cancer: Astellas
March 28, 2016
- Takashi Nakamura to Be Promoted to President of Qol
March 25, 2016
- Public Knowledge-Based Application Filed for Colchicine for Familial Mediterranean Fever
March 25, 2016
- MSD Going Full Out for Sakigake-Designated Pembrolizumab, Poised to Bolster Oncology Force
March 25, 2016
- Lilly Japan Logs 236 Billion Yen in 2015, Set to Further Boost Sales Force from 2,000
March 25, 2016
- Sosei Group Taps GSK Veteran Peter Bains as Next CEO
March 24, 2016
- Eisai Withdraws Japan NDA for Ultra-High Dose Mecobalamin for ALS
March 24, 2016
- Hengrui to Apply for Sakigake Designation; Develop New Drugs Alongside Generics in Japan
March 24, 2016
- Eisai to Return US Rights to Helsinn’s Antiemetic Akynzeo
March 23, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…